AlphAIalphai — Financial news for AI agents
punchng.comAUG 282 min read

Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics reported $25.3M in MYQORZO sales for Q2, with 700+ healthcare providers prescribing it. Armistice Capital increased its stake by 57% to 1.2M shares. The company plans to submit a supplemental drug application for non-obstructive HCM in Q4 2026. Total revenue fell to $28.6M from $66.8M YoY due to lower collaboration payments. Cytokinetics ended Q2 with $1.7B in cash and investments.

Original reporting
punchng.com
Published Aug 28, 2026, 7:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position — source image
Source · punchng.com
Decision brief

The 30-second read

Med
01

Why it matters

The ACACIA-HCM data could drive a re‑rating and increase demand for CKPT shares ahead of the Q4 supplemental NDA filing.

02

Market read

First report of pivotal trial results for a new HCM indication; likely to move CKPT and influence cardiology biotech peers.

03

What to watch

Potential regulatory delays in non‑US markets and competition from other HCM candidates.

Relevance 9/10Novelty 9/10Timing: today

Background

Cytokinetics' MYQORZO launched in Q2 2025; the company now seeks to expand its label to non‑obstructive HCM based on new trial data.

Market effects

Sector

Strengthens the HCM therapeutic pipeline, may benefit peer biotech stocks in cardiology.

Regional

US and European markets could see modest gains in biotech indices.

Global

Highlights ongoing innovation in cardiovascular therapies worldwide.

Counterpoint

What could challenge this read

Safety concerns with higher LVEF drop rates could outweigh efficacy gains, prompting a sell‑off.

Key entities

  • company
    Cytokinetics

    Biopharma developing aficamten (MYQORZO) for hypertrophic cardiomyopathy.

  • investor
    Armistice Capital

    Hedge fund increasing its stake in Cytokinetics.

Read at source← All news

Related articles

AUG 28
$CYTKMedAI 8/10

Why Cytokinetics (CYTK) Stock Is Down Today

Cytokinetics (CYTK) shares fell 7.7% following the release of full Phase 3 ACACIA-HCM trial data for aficamten, which met primary endpoints but showed treatment interruptions and adverse events. The next milestone is a 2026 FDA filing. Investors may have already priced in positive topline results from May.

quiverquant.com2 min
AUG 28
$CYTKMedAI 8/10

CYTK Looks 64.3% Undervalued on GF Value™ Despite Profitability

Cytokinetics Inc (CYTK) saw its stock decline after detailed Phase 3 trial data for Myqorzo was released. The company plans to file an FDA application in Q4 2026. CYTK trades at a high P/S ratio of 136.11, with a GF Value™ suggesting it is 64.3% undervalued. The GF Score™ is 51/100, indicating moderate fundamentals with weak profitability and financial strength. Insiders have sold $43.7M in shares, while 8 gurus hold positions, with mixed activity.

gurufocus.com3 min
AUG 14
$CAPRMedAI 8/10

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.

finance.yahoo.com4 min
AUG 13
$CYTKMedAI 8/10

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.

fool.com10 min
AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstruc

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min